UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models

CPT: pharmacometrics and systems pharmacology, 2014-02, Vol.3 (2), p.1-3

Agoram, B

2014

Volltextzugriff (PDF)

A Mathematical Modeling Approach to Understanding the Effect of Anti‐Interleukin Therapy on Eosinophils

CPT: pharmacometrics and systems pharmacology, 2016-11, Vol.5 (11), p.608-616

2016

Volltextzugriff (PDF)

Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation

CPT: pharmacometrics and systems pharmacology, 2017-08, Vol.6 (8), p.496-498

2017

Volltextzugriff (PDF)

THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

Hematological oncology, 2019-06, Vol.37 (S2), p.89-90

2019

Volltextzugriff (PDF)

Systems Pharmacology Models Can Be Used to Understand Complex Pharmacokinetic‐Pharmacodynamic Behavior: An Example Using 5‐Lipoxygenase Inhibitors

CPT: pharmacometrics and systems pharmacology, 2013-09, Vol.2 (9), p.1-9

2013

Volltextzugriff (PDF)

Effects of IL‐1β–Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms

CPT: pharmacometrics and systems pharmacology, 2014-06, Vol.3 (6), p.1-8

2014

Volltextzugriff (PDF)

Coupled macroscopic and microscopic scale modeling of fibrillar tissues and tissue equivalents

Journal of biomechanical engineering, 2001-08, Vol.123 (4), p.362-369

2001

Volltextzugriff (PDF)

Predicting the impact of physiological and biochemical processes on oral drug bioavailability

Advanced drug delivery reviews, 2001-10, Vol.50, p.S41-S67

2001

Volltextzugriff (PDF)

The role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologics

Drug discovery today, 2007-12, Vol.12 (23), p.1018-1024

2007

Volltextzugriff (PDF)

Development and evaluation of a population pharmacokinetic (PK) model for darbepoetin alfa in healthy subjects

Clinical pharmacology and therapeutics, 2005-02, Vol.77 (2), p.P76-P76

2005

Volltextzugriff (PDF)

Characterization of dose-FEV1 response of tralokinumab, an investigational anti-IL13 monoclonal antibody in patients with uncontrolled asthma: a population pharmacokinetic/pharmacodynamic modeling analysis

Allergy (Copenhagen), 2015, Vol.70 (S101), p.35

2015

Volltextzugriff (PDF)

C26 ASTHMA IN INFANTS AND CHILDREN: Pharmacokinetic And Safety Evaluation Of Tezepelumab In Adolescents With Mild To Moderate Asthma

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

Development of a pharmacokinetic pharmacodynamic (PKPD) model to predict onset of hemolytic anemia in (PEG)interferon/ribavirin treated hepatitis-C virus (HCV)-infected patients

Clinical pharmacology and therapeutics, 2004-02, Vol.75 (2), p.P78-P78

2004

Volltextzugriff (PDF)

A32 NEW ASTHMA THERAPIES: CLINICAL STUDIES: Tralokinumab, An Investigational Anti-Il-13 Monoclonal Antibody In Asthma, Does Not Require Dose Adjustment In Adolescent Subjects Compared With Adults: A Pharmacokinetic Investigation

American journal of respiratory and critical care medicine, 2014-01, Vol.189, p.1

2014

Volltextzugriff (PDF)

Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation: Methodologies for Quantitative Systems

CPT: pharmacometrics and systems pharmacology, 2017-08, Vol.6 (8), p.496-498

2017

Volltextzugriff (PDF)

S867 THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

HemaSphere, 2019-06, Vol.3 (S1), p.388-n/a

2019

Volltextzugriff (PDF)

S878 THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 IS ACTIVE AND WELL TOLERATED ALONE OR IN COMBINATION WITH AZACITIDINE IN AML AND MDS PATIENTS: INITIAL PHASE 1B RESULTS

HemaSphere, 2019-06, Vol.3 (S1), p.394-n/a

2019

Volltextzugriff (PDF)

561 Pharmacokinetic-pharmacodynamic modeling and simulation of darbepoetin alfa once-monthly dosing regimen for the design of clinical trials in anemic patients with chronic heart failure

European journal of heart failure. Supplements, 2006-06, Vol.5 (Suppl), p.126-126

2006

Volltextzugriff (PDF)

A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients

Journal of clinical oncology, 2020-02, Vol.38 (5_suppl), p.18-18

2020

Volltextzugriff (PDF)

Once-Monthly Administration of Darbepoetin Alfa for the Treatment of Patients with Chronic Heart Failure and Anemia: A Pharmacokinetic and Pharmacodynamic Investigation

Journal of cardiovascular pharmacology, 2005-08, Vol.46 (2), p.155-161

2005

Volltextzugriff (PDF)

Simulation of Absorption, Metabolism, and Bioavailability

Drug Bioavailability, 2003, p.420-443

2003

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)
Buchkapitel
(1)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models

A Mathematical Modeling Approach to Understanding the Effect of Anti‐Interleukin Therapy on Eosinophils

Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation

THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

Systems Pharmacology Models Can Be Used to Understand Complex Pharmacokinetic‐Pharmacodynamic Behavior: An Example Using 5‐Lipoxygenase Inhibitors

Effects of IL‐1β–Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms

Coupled macroscopic and microscopic scale modeling of fibrillar tissues and tissue equivalents

Predicting the impact of physiological and biochemical processes on oral drug bioavailability

The role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologics

Development and evaluation of a population pharmacokinetic (PK) model for darbepoetin alfa in healthy subjects

Characterization of dose-FEV1 response of tralokinumab, an investigational anti-IL13 monoclonal antibody in patients with uncontrolled asthma: a population pharmacokinetic/pharmacodynamic modeling analysis

C26 ASTHMA IN INFANTS AND CHILDREN: Pharmacokinetic And Safety Evaluation Of Tezepelumab In Adolescents With Mild To Moderate Asthma

Development of a pharmacokinetic pharmacodynamic (PKPD) model to predict onset of hemolytic anemia in (PEG)interferon/ribavirin treated hepatitis-C virus (HCV)-infected patients

A32 NEW ASTHMA THERAPIES: CLINICAL STUDIES: Tralokinumab, An Investigational Anti-Il-13 Monoclonal Antibody In Asthma, Does Not Require Dose Adjustment In Adolescent Subjects Compared With Adults: A Pharmacokinetic Investigation

Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation: Methodologies for Quantitative Systems

S867 THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

S878 THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 IS ACTIVE AND WELL TOLERATED ALONE OR IN COMBINATION WITH AZACITIDINE IN AML AND MDS PATIENTS: INITIAL PHASE 1B RESULTS

561 Pharmacokinetic-pharmacodynamic modeling and simulation of darbepoetin alfa once-monthly dosing regimen for the design of clinical trials in anemic patients with chronic heart failure

A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients

Once-Monthly Administration of Darbepoetin Alfa for the Treatment of Patients with Chronic Heart Failure and Anemia: A Pharmacokinetic and Pharmacodynamic Investigation

Simulation of Absorption, Metabolism, and Bioavailability

Suchergebnisse filtern